Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1159.02 | +2.4% | 1.9M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.5t | $231.90 | -0.4% | 2.5M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $384.7b | $222.33 | -2.2% | 1.7M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $293.2b | $119.85 | -0.8% | 3.1M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $287.9b | $183.68 | -1.2% | 1.0M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $183.0b | $471.65 | -0.2% | 517.5K |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $181.8b | $345.87 | -1.1% | 726.4K |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $166.9b | $127.69 | -1.1% | 2.2M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $149.2b | $25.80 | -0.9% | 15.7M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $116.8b | $56.28 | -1.7% | 4.6M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $113.6b | $446.12 | -0.2% | 302.3K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $64.5b | $617.68 | -2.8% | 235.2K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.3b | $290.84 | -4.0% | 657.7K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $38.2b | $133.43 | -1.5% | 368.2K |
 WAT | Waters Corp | Clinical-Stage Platforms | $37.7b | $364.45 | -0.2% | 203.2K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $30.4b | $182.31 | -0.6% | 247.8K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $28.9b | $194.43 | -0.5% | 361.4K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $24.7b | $55.64 | -0.4% | 1.4M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.6b | $548.00 | -0.3% | 129.4K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $23.2b | $95.23 | +1.1% | 2.1M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $22.8b | $318.79 | +1.4% | 109.3K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $21.6b | $28.63 | +0.2% | 1.3M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $19.3b | $101.05 | -1.3% | 983.8K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $18.7b | $47.88 | +0.9% | 1.6M |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $15.9b | $163.59 | -0.2% | 193.1K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $14.8b | $235.03 | -1.5% | 464.4K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $13.8b | $205.65 | -2.3% | 191.4K |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.6b | $14.41 | -2.4% | 1.4M |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.0b | $67.78 | +0.2% | 411.8K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $12.8b | $455.67 | +0.3% | 60.5K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.6b | $73.97 | -0.7% | 469.2K |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $12.1b | $237.79 | +2.4% | 199.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.8b | $21.50 | +7.6% | 56.8K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $11.7b | $101.13 | +2.8% | 420.2K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $474.21 | -2.6% | 81.2K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $56.25 | -0.9% | 399.3K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.0b | $73.77 | +0.9% | 355.0K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.4b | $69.27 | -3.1% | 700.9K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $10.4b | $151.49 | +1.4% | 363.0K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.8b | $257.17 | +1.2% | 236.6K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.1b | $304.68 | +1.2% | 61.7K |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.0b | $57.03 | +1.1% | 811.6K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $8.7b | $184.04 | +1.5% | 222.2K |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $306.58 | +0.8% | 2 |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $53.05 | +2.0% | 1.4M |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.9b | $71.55 | +0.0% | 535.5K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $7.9b | $7.14 | +3.2% | 5.4M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $7.5b | $36.47 | -0.6% | 550.0K |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $7.5b | $74.85 | +3.1% | 244.6K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.4b | $46.25 | -2.3% | 264.2K |